3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Carcinoma, Hepatocellular
2
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Everolimus
7
lutetium Lu 177 dotatate
4
lanreotide
4
Sunitinib
4
Temozolomide
3
Octreotide
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Fluorodeoxyglucose F18
3
Capecitabine
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
copper dotatate CU-64
2
amino-acid, glucose, and electrolyte solution
2
Quality of Life
2
FAPI-46
2
veliparib
1
tivozanib
1
tislelizumab
1
telotristat ethyl
1
surufatinib
1
romidepsin
1
repotrectinib
1
pralsetinib
1
pembrolizumab
1
pasireotide
1
gallium Ga 68 dotatate
1
gadoteridol
1
gadoterate meglumine
1
gadolinium ethoxybenzyl DTPA
1
gadodiamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
gadoterate meglumine
×
Gastrointestinal
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled